Examining mCRC Chemotherapy Costs, Patient Outcomes in Washington vs British Columbia

Todd Yezefski, MD

Todd Yezefski, MD, a senior fellow in the Clinical Research Division at the Fred Hutchinson Cancer Research Center, discusses the results of a trial investigating cost and outcome differences in patients with metastatic colorectal cancer in the United States and Canada. Specifically, he looked at patients in Washington and British Columbia. This data was presented at the 2018 ASCO Annual Meeting.

Todd Yezefski, MD, a senior fellow in the Clinical Research Division at the Fred Hutchinson Cancer Research Center, discusses the results of a trial investigating cost and outcome differences in patients with metastatic colorectal cancer in the United States and Canada. Specifically, he looked at patients in Washington and British Columbia. This data was presented at the 2018 ASCO Annual Meeting.

He and his team found that the cost of chemotherapy treatments was almost double in Washington compared with British Columbia. While patients in Washington were paying almost $12,000 dollars per month per patient, those in British Columbia were only paying a little more than $6,000 dollars per month.